Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
121.4 USD | -0.07% | -1.08% | +11.39% |
Mar. 15 | Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time | RE |
Mar. 15 | Merck: promising new results for Keytruda | CF |
Financials (USD)
Sales 2024 * | 63.74B | Sales 2025 * | 67.94B | Capitalization | 308B |
---|---|---|---|---|---|
Net income 2024 * | 19.92B | Net income 2025 * | 22.25B | EV / Sales 2024 * | 5.12 x |
Net Debt 2024 * | 18.9B | Net Debt 2025 * | 7.72B | EV / Sales 2025 * | 4.64 x |
P/E ratio 2024 * |
15.4
x | P/E ratio 2025 * |
13.5
x | Employees | 71,000 |
Yield 2024 * |
2.64% | Yield 2025 * |
2.8% | Free-Float | 70.76% |
Latest transcript on Merck & Co., Inc.
1 day | -0.07% | ||
1 week | -1.67% | ||
Current month | -4.49% | ||
1 month | -4.97% | ||
3 months | +15.54% | ||
6 months | +12.95% | ||
Current year | +11.39% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 66 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.34% | 227 M€ | +9.20% | - | |
5.61% | 18 M€ | +4.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 121.4 | -0.07% | 8,311,596 |
24-03-15 | 121.5 | +0.84% | 46,477,417 |
24-03-14 | 120.5 | -1.35% | 10,132,544 |
24-03-13 | 122.2 | -0.41% | 9,186,104 |
24-03-12 | 122.7 | -0.09% | 11,621,795 |
Delayed Quote Nyse, March 18, 2024 at 04:01 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.39% | 308B | |
+30.83% | 679B | |
+30.96% | 589B | |
+0.01% | 381B | |
+15.18% | 314B | |
+0.78% | 212B | |
-6.09% | 210B | |
-2.92% | 203B | |
-3.72% | 158B | |
-5.94% | 144B |